The Arab Drug Company (EGX:ADCI)

The Arab Drug Company Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	253.56	227.86	102.82	82.77	76.3	101.41
Depreciation & Amortization	25,370	25,361	3.37	3.26	9.39	7.81
Other Operating Activities	-25,442	-25,424	29.58	1.48	-52.82	-72.65
Operating Cash Flow	181.38	164.28	135.77	87.51	32.87	36.58
Operating Cash Flow Growth	27.82%	21.00%	55.15%	166.22%	-10.14%	-50.05%
Capital Expenditures	-111.36	-164.65	-218.95	-63.18	-89.92	-28.87
Investment in Securities	-34.25	-34.25	-67.03	-	13.88	-
Other Investing Activities	11.84	19.27	27.92	1.07	1.63	4.34
Investing Cash Flow	-133.78	-179.63	-258.07	-62.11	-74.41	-24.53
Short-Term Debt Issued	-	-	-	-	27.33	-
Long-Term Debt Issued	-	35.79	339.09	51.3	52.54	-
Total Debt Issued	27.4	35.79	339.09	51.3	79.87	-
Long-Term Debt Repaid	-	-97.24	-44.55	-	-	-
Total Debt Repaid	-87.05	-97.24	-44.55	-	-	-
Net Debt Issued (Repaid)	-59.65	-61.46	294.54	51.3	79.87	-
Common Dividends Paid	-63.12	-63.11	-36.1	-37.49	-43.54	-38.85
Other Financing Activities	-52.25	-48.56	-23.09	-1.68	-0.95	-
Financing Cash Flow	-175.02	-173.12	235.35	12.13	35.38	-38.85
Miscellaneous Cash Flow Adjustments	52.96	35.04	69.18	-27.33	-	-0
Net Cash Flow	-74.46	-153.44	182.24	10.2	-6.15	-26.8
Free Cash Flow	70.02	-0.38	-83.19	24.33	-57.04	7.71
Free Cash Flow Growth	-	-	-	-	-	-89.09%
Free Cash Flow Margin	5.88%	-0.03%	-10.59%	3.84%	-11.29%	1.44%
Free Cash Flow Per Share	5.83	-0.03	-6.93	2.03	-4.21	0.56
Cash Interest Paid	52.25	48.56	23.09	1.68	0.95	-
Cash Income Tax Paid	46.26	47.18	34.73	35.09	51.95	52.97
Levered Free Cash Flow	25,370	25,218	-117.59	-24.95	-121.56	-1.96
Unlevered Free Cash Flow	25,403	25,248	-103.16	-23.5	-120.96	-1.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.